title: Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
abstract: Clinical studies of treatment with angiotensin converting enzyme (ACE) inhibitors in patients with glomerular disease have shown the clinical efficacy of these agents. Fifteen renal transplant hypertensive and proteinuric patients on triple drug treatment with cyclosporin (CSA), azathioprine and methylprednisolone entered the therapeutic protocol of this study. All patients followed up last year had stable graft function (serum creatinine less than 2 mg/dl). Hypertension was treated by nifedipine retard and occasionally by furosemide. Patients with a renal artery graft stenosis, at least as judged by technetium-scan imaging were excluded. In order to evaluate the possible role of ACE inhibitors on hypertension and proteinuria, perindopril 4 mg/daily was added for two months to the above regimen. Two patients, who showed a reversible deterioration of renal function during treatment and three who did not comply to the therapeutic protocol were excluded. Systolic and diastolic blood pressure as well as 24 h urine protein was found to be significantly (p < 0.01) reduced at the end of the two-month combined treatment with perindopril and nifedipine retard in comparison to the result of monotherapy with nifedipine retard. GFR and ERPF showed no significant difference (NS) between the two modes of treatment. It is suggested that the combined treatment with nifedipine retard and perindopril is more effective than the monotherapy with nifedipine retard in the management of moderate to severe post-transplant hypertension and proteinuria of renal transplant patients.
authors.affiliation: First Medical Department, University Hospital AHEPA, Thessaloniki, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Grekas
authors.forename: C
authors.initials: C
authors.lastname: Dioudis
authors.forename: I
authors.initials: I
authors.lastname: Kalevrosoglou
authors.forename: F
authors.initials: F
authors.lastname: Papoulidou
authors.forename: N
authors.initials: N
authors.lastname: Goutsaridis
authors.forename: P
authors.initials: P
authors.lastname: Alivanis
authors.forename: A
authors.initials: A
authors.lastname: Tourkantonis
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007211:Indoles / Q000627:therapeutic use*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D020913:Perindopril; D011446:Prospective Studies; D011507:Proteinuria / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012964:Sodium / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D007211:Indoles; D012964:Sodium; D003404:Creatinine; D009543:Nifedipine; D020913:Perindopril